Forefront Analytics’s Unity Biotechnology UBX Stock Holding History

Forefront Analytics’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,038	Closed	-$11K	–	69
2022 Q2	$11K	Buy	+2,038	New	+$17K	0.01%	66

Other funds holding UBX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

ACM

Altium Capital Management New York $42M AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Forefront Analytics's UBX Position: Q3 2022 in Review

Forefront Analytics sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 2,038 shares — an estimated $11K sold.

Forefront Analytics first reported a position in UBX in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

Forefront Analytics reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
Forefront Analytics sold 2,038 Unity Biotechnology shares in Q3 2022, an estimated $11K.
Forefront Analytics first reported a position in Unity Biotechnology in Q2 2022 and held it in 1 quarter.
Forefront Analytics's Unity Biotechnology position peaked at $11K in Q2 2022.
72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Forefront Analytics's 13F filing for Q3 2022, filed 14 Nov 2022.